Clinical trials: Hyperlipemia, Mixed
Mixed Dyslipidemia, Hypercholesterolaemia
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
This Phase 3, randomized, double-blind, active-controlled study evaluates the efficacy and safety of obicetrapib (OBI) compared to bempedoic acid (BPA) in participants with dyslipidemia at high or very high cardiovascular risk.
- Trial name
- MEDICI (NCT07614958)
- Where
- United Kingdom
- Volunteers
- 426 people
- Sponsor
- A. Menarini International Licensing S.A.
Hypertriglyceridemia, Mixed Hyperlipidemia
A Pilot Study to Evaluate the Lipid Effects of TRIA-662
The purpose of this pilot study is to learn what study factors are important in designing a large, full-scale study of the effects of TRIA-662 on serum triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) levels.
- Trial name
- NCT02008084
- Testing
- TRIA-662
- Where
- 17 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Cortria Corporation
Hypercholesterolemia, Mixed Dyslipidemia
Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
The primary objective is to describe in the real-world setting patient characteristics and outcomes of patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia using bempedoic…
- Trial name
- MILOS (NCT04579367)
- Testing
- Bempedoic acid and/or its fixed-dose combination with ezetimibe
- Where
- 443 sites in Austria, Belgium and 6 more
- Volunteers
- 5,000 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Hyperlipidemia
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.
- Trial name
- SPIRE-HR (NCT01968954)
- Testing
- Bococizumab (PF-04950615;RN316)
- Where
- 103 sites in United States, Australia and 7 more
- Volunteers
- 711 people
- Sponsor
- Pfizer
Hypercholesterolemia, Mixed Dyslipidemia
A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients
The purpose of this study was to describe the effectiveness of inclisiran and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in the real-world setting in China.
- Trial name
- NCT07409636
- Where
- United States
- Volunteers
- 11,991 people
- Sponsor
- Novartis Pharmaceuticals
Mixed Dyslipidemia, Hypercholesterolemia
Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia
The purpose of the study is to evaluate the safety and tolerability of fluvastatin 80 mg in a Chinese population. This study is not recruiting patients in the US.
- Trial name
- NCT00136799
- Testing
- Fluvastatin
- Where
- China
- Volunteers
- 325 people
- Sponsor
- Novartis
Hyperlipidemia
A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia
This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.
- Trial name
- NCT05255094
- Testing
- AK102
- Where
- China
- Volunteers
- 464 people
- Sponsor
- Akeso
Hypercholesterolemia, Hyperlipidemia, Familial Combined
Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol
The primary objective of this study is to compare the effect of Welchol in combination with TriCor compared to TriCor alone on low-density lipoprotein cholesterol (LDL-C) in patients with high cholesterol.
- Trial name
- NCT00754039
- Testing
- colesevelam HCl tablets and fenofibrate tablets
- Where
- 10 sites in United States
- Volunteers
- 129 people
- Sponsor
- Daiichi Sankyo
Dyslipidemia
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
The primary purpose of your participation in this study is to help answer the following research question(s) Whether LY2484595 in combination with a statin drug (atorvastatin, simvastatin or rosuvastatin; currently used to treat…
- Trial name
- NCT01105975
- Testing
- LY2484595, Atorvastatin, Simvastatin
- Where
- 59 sites in United States, Denmark and 4 more
- Volunteers
- 398 people
- Sponsor
- Eli Lilly and Company
Primary Hypercholesterolemia or Mixed Hyperlipidemia
A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan
Cardiovascular disease (CVD) is a chronic non-communicable disease among the most common causes of death worldwide. Substantial reductions in risks of CVD can be achieved through the management of modifiable risk factors…
- Trial name
- CLEAR Taiwan (NCT06925100)
- Testing
- Bempedoic acid 180 mg tablet
- Where
- 3 sites in Taiwan
- Volunteers
- 180 people
- Sponsor
- Daiichi Sankyo
Primary Hypercholesterolaemia, Mixed Hyperlipidaemia
Lipid Efficacy/Tolerability Study (0524A-020)
A 28-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia to study the effects of MK0524A on lipids and tolerability. There will be 9 scheduled clinic visits, and 3 treatment groups.
- Trial name
- NCT00269204
- Testing
- niacin (+) laropiprant, ER-niacin
- Volunteers
- 1,620 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.
- Trial name
- SPIRE-LDL (NCT01968967)
- Testing
- Bococizumab (PF-04950615; RN316)
- Where
- 249 sites in United States, Canada and 10 more
- Volunteers
- 2,139 people
- Sponsor
- Pfizer
Hyperlipidemia, Mixed Dyslipidemia
An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)
To demonstrate that niacin ER and simvastatin (NS) tablets, when compared to atorvastatin (Lipitor®; Pfizer, Inc.), has superior high-density lipoprotein cholesterol (HDL-C) elevating effects at Week 12 in subjects with type II…
- Trial name
- SUPREME (NCT00465088)
- Testing
- Niacin ER/Simvastatin Tablets, atorvastatin
- Where
- 46 sites in United States
- Volunteers
- 199 people
- Sponsor
- Abbott
Hypercholesterolaemia, Mixed Dyslipidaemia
Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.
Single dose oral bioequivalence study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated tablets in healthy adult human subjects under fasting conditions.
- Conditions
- Hypercholesterolaemia, Mixed Dyslipidaemia, Cardiovascular Diseases
- Trial name
- NCT06923956
- Testing
- Bempedoic Acid Film Coated Tablet, Nilemdo® (Bempedoic Acid) Film-coated tablets
- Where
- India
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Hyperlipidemia, Dyslipidemia
Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia
The purpose of this study is to compare the efficacy of NK-104-CR with Placebo and Livalo® on the reduction of LDL-C and to evaluate the safety of NK-104-CR in patients with primary hyperlipidemia or mixed dyslipidemia
- Trial name
- NCT02670434
- Testing
- NK-104-CR, Livalo
- Where
- 45 sites in United States
- Sponsor
- Kowa Research Institute, Inc.
Hyperlipidemia
Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
This study is a multicenter, randomized study in subjects with high cholesterol receiving statins to assess the efficacy to lower LDL-C, the safety, tolerability and actual use of bococizumab and an autoinjector (pre-filled pen).
- Trial name
- SPIRE-AI (NCT02458287)
- Testing
- Bococizumab 150mg, Bococizumab 75mg
- Where
- 30 sites in United States
- Volunteers
- 299 people
- Sponsor
- Pfizer
Primary Hypercholesterolemia, Mixed Dyslipidemia
Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in home-use using either a pre-filled syringe or autoinjector/pen.
- Trial name
- NCT01849497
- Testing
- Evolocumab Pre-filled Syringe, Evolocumab AI/pen
- Where
- 26 sites in United States, Canada
- Volunteers
- 149 people
- Sponsor
- Amgen
Hypercholesterolemia, Hyperlipidemia
Effect of MK0524A on Cholesterol Levels (0524A-048)
The primary objective of the study is to assess the effects of MK0524A in reducing cholesterol levels in an Asian population.
- Trial name
- NCT00536510
- Testing
- laropiprant/niacin (MK0524A)
- Volunteers
- 646 people
- Sponsor
- Merck Sharp & Dohme LLC
Cardiovascular Diseases
Comparison of the Combination of Fenofibrate and 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia.
- Trial name
- NCT00352183
- Testing
- Fenofibrate/Simvastatin, Simvastatin
- Where
- 67 sites in Australia, Estonia and 4 more
- Volunteers
- 450 people
- Sponsor
- Solvay Pharmaceuticals
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) in combination with statin therapy (atorvastatin) on percent change from baseline in low-density lipoprotein…
- Trial name
- BERSON (NCT02662569)
- Testing
- Evolocumab, Atorvastatin
- Where
- 110 sites in United States, Argentina and 8 more
- Volunteers
- 986 people
- Sponsor
- Amgen